Ethicon Launches ECHELON ENDOPATH Staple Line Reinforcement: Reduces Complications Associated with Bariatric, Thoracic and General Surgical Procedures

Offers Significant Improvements Over Existing Buttressing Solutions

Ethicon, part of Johnson & Johnson Medical Devices Companies, announced today the launch of ECHELON ENDOPATH Staple Line Reinforcement (SLR), a novel buttressing device designed to further strengthen staple lines and reduce potential complications during bariatric, thoracic and general surgical procedures. This is the company’s first buttress solution designed for use with its own industry-leading ECHELON FLEX™ Powered Staplers with GST reloads, which have been associated with a lower rate of air leaks and bleeding complications.[i],[ii] 

Ethicon developed the ECHELON ENDOPATH SLR to help surgeons who want even more strength around the staple line and to overcome issues with current buttressing options which can be difficult to load, result in inconsistent staple line coverage and may loosen with typical maneuvering during stapling procedures.

“The ECHELON ENDOPATH SLR takes a different approach to buttressing that offers significant improvements in ease of use, functionality and OR efficiency.[iii]  For those who buttress, I expect this will become their preferred solution,” said Neil Floch MD, FACS, Director of Minimally Invasive and Bariatric Surgery, Norwalk Hospital.***

Designed for ease of use, the ECHELON ENDOPATH SLR delivers a seamless buttress experience from start to finish.[iv] The device’s simple click-and-go applicator and proprietary buttress attachment material are designed for precise control, consistent and quicker loading, and a more secure attachment for uninterrupted tissue manipulation and release.[v] The new device prevents the slipping, twisting, sliding or bunching that can occur with other buttress options and provides greater stability when manipulating tissue.[vi]

The ECHELON ENDOPATH SLR also provides exceptional coverage after tissue manipulation. Studies show 100% of its applications covered all staples with buttress[vii] compared to 28%[viii] for GORE® SEAMGUARD® Bioabsorbable SLR and 0% for Medtronic’s Endo GIA™ Reinforced Reload with Tri-Staple Technology.[ix] The Ethicon device also showed higher average reinforcement,[x] and takes fewer steps and less time to load than the GORE product.[xi]

“The launch of the ECHELON ENDOPATH SLR marks a new milestone in Ethicon’s continuing commitment to provide a better way to staple, and now a better way to buttress, when needed in minimally-invasive surgical procedures,” said Tom O’Brien, Worldwide President Endomechanical, Ethicon, Inc.  “At Ethicon, we continually look for ways to optimize usability for surgeons and improve patient outcomes.”


[i] Miller DL, Roy S, Kassis ES. et al. Impact of powered and tissue-specific endoscopic stapling technology on clinical and economic outcomes of video-assisted thoracic surgery lobectomy procedures: a retrospective, observational study. Advances in Therapy (2018). https://doi.org/10.1007/s12325-018-0679-z.

[ii] Klassen C, Eckert CE, Wong J. et al. Ex Vivo Modeling of Perioperative Air Leaks in Porcine Lungs. IEEE Transactions on Biomedical Engineering (2018). https://ieeexplore.ieee.org/document/8325303/

[iii] Wong JB, Henninger DD, Clymer JW. et al. A Novel, Easy-to-Use Staple Line Reinforcement for Surgical Staplers. Medical Devices: Evidence and Research. 2020:12 23-29.

[iv] Based on coverage after manipulation assessment on porcine tissue.

[v] Based on coverage after manipulation assessment on porcine tissue.

[vi] Based on coverage after manipulation assessment on porcine tissue.

[vii] In a tissue test ECHELON ENDOPATH™ Reinforcement covered all staple legs in (40/40) applications compared to GORE™ SEAMGUARD™ (11/40), p<0.05.

[viii]  In a tissue test ECHELON ENDOPATH™ Reinforcement covered all staple legs in (40/40) applications compared to GORE™ SEAMGUARD™ (11/40), p<0.05.

[ix] In a tissue test ECHELON ENDOPATH™ Staple Line Reinforcement fully covered staple legs in (15/15) applications compared to Endo GIA™ Reinforced Reload with Tri-Staple™ Technology (0/15), p<0.05.

[x] Reinforcement measured via in vitro staple pull-through force at T=0, T=7, and T=14 days resulting in mean values: ECHELON ENDOPATH™ Reinforcement (22.02N, 10.65N, 2.93N) vs. GORE® SEAMGUARD® Reinforcement (7.33N, 5.52N, 2.35N), p<0.05. 109221-190311

[xi] Ricketts C, Pollack E. Evaluation of setup by nurses of a novel click and go staple line reinforcement system. Glob Surg. 2020;6. doi:10.15761/GOS.1000215.

SourceEthicon
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy